Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs

被引:16
作者
Madsen, Melanie [1 ]
Messenger, Kristen [1 ]
Papich, Mark G. [1 ]
机构
[1] North Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA
关键词
CIPROFLOXACIN PHARMACOKINETICS; IN-VITRO; ABSORPTION;
D O I
10.2460/ajvr.80.10.957
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
OBJECTIVE To determine the pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and IV administration to dogs and whether the achieved plasma levofloxacin concentration would be sufficient to treat susceptible bacterial infections. ANIMALS 6 healthy adult Beagles. PROCEDURES Levofloxacin was administered orally as a generic 250-mg tablet (mean dose, 23.7 mg/kg) or IV as a solution (15 mg/kg) to each dog in a crossover study design, with treatments separated by a minimum 2-day washout period. Blood samples were collected at various points for measurement of plasma levofloxacin concentration via high-pressure liquid chromatography. Pharmacokinetic analysis was performed with compartmental modeling. RESULTS After oral administration of the levofloxacin tablet, mean (coefficient of variation) peak plasma concentration was 15.5 mu g/mL (23.8%), mean elimination half-life was 5.84 hours (20.0%), and mean bioavailability was 104% (29.0%). After IV administration, mean elimination half-life (coefficient of variation) was 6.23 hours (14.7%), systemic clearance was 145.0 mL/kg/h (22.2%), and volume of distribution was 1.19 L/kg (17.1%). CONCLUSIONS AND CLINICAL RELEVANCE In these dogs, levofloxacin was well absorbed when administered orally, and a dose of approximately 25 mg/kg was sufficient to reach pharmacokinetic-pharmacodynamic targets for treating infections with susceptible Enterobacteriaceae (ie, <= 0.5 mu g/mL) or Pseudomonas aeruginosa (ie, <= 1 mu g/mL) according to clinical breakpoints established by the Clinical and Laboratory Standards Institute.
引用
收藏
页码:957 / 962
页数:6
相关论文
共 17 条
[1]  
[Anonymous], 2008, LEV LEV MED GUID
[2]  
Clinical and Laboratory Standards Institute, 2018, Performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes
[3]  
CLSI, 2016, M100 CLSI, V26th
[4]  
CLSI, 2018, VET08 CLSI
[5]  
CLSI, 2019, CLSI rationale document MR02, V1st
[6]   LEVOFLOXACIN A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETICS AND THERAPEUTIC EFFICACY [J].
DAVIS, R ;
BRYSON, HM .
DRUGS, 1994, 47 (04) :677-700
[7]  
Eliopoulos G M, 1995, Drugs, V49 Suppl 2, P48
[8]   The clinical pharmacokinetics of levofloxacin [J].
Fish, DN ;
Chow, AT .
CLINICAL PHARMACOKINETICS, 1997, 32 (02) :101-119
[9]   In vitro susceptibility of anaerobes to quinolones in the United States [J].
Hecht, DW ;
Wexler, HM .
CLINICAL INFECTIOUS DISEASES, 1996, 23 :S2-S8
[10]   Glomerular filtration rate in dogs as estimated via plasma clearance of inulin and iohexol and use of limited-sample methods [J].
Heiene, Reidun ;
Eliassen, Knut A. ;
Risoen, Unni ;
Neal, Larry A. ;
Cowgill, Larry D. .
AMERICAN JOURNAL OF VETERINARY RESEARCH, 2010, 71 (09) :1100-1107